|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
18
|
|
pubmed:dateCreated |
2008-9-16
|
|
pubmed:abstractText |
Tamoxifen has been the mainstay adjuvant hormonal treatment for breast cancer for many years. Conversion of tamoxifen to its active metabolite, endoxifen, is reduced by low activity of the cytochrome P450 enzyme, CYP2D6. We examined the effect of reduced CYP2D6 activity on the response to tamoxifen in patients with familial early-onset breast cancer.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
14
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
5913-8
|
|
pubmed:meshHeading |
pubmed-meshheading:18794105-Adult,
pubmed-meshheading:18794105-Aged,
pubmed-meshheading:18794105-Breast Neoplasms,
pubmed-meshheading:18794105-Cytochrome P-450 CYP2D6,
pubmed-meshheading:18794105-Estrogen Antagonists,
pubmed-meshheading:18794105-Female,
pubmed-meshheading:18794105-Genes, BRCA1,
pubmed-meshheading:18794105-Genes, BRCA2,
pubmed-meshheading:18794105-Genotype,
pubmed-meshheading:18794105-Humans,
pubmed-meshheading:18794105-Middle Aged,
pubmed-meshheading:18794105-Mutation,
pubmed-meshheading:18794105-Survival Analysis,
pubmed-meshheading:18794105-Tamoxifen
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Impaired tamoxifen metabolism reduces survival in familial breast cancer patients.
|
|
pubmed:affiliation |
Department of Medical Genetics, St. Mary's Hospital, University of Manchester, Manchester, United Kingdom. William.newman@manchester.ac.uk
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
